David Busse1,2, André Schaeftlein3, Alexander Solms4,5, Luis Ilia1, Robin Michelet1, Markus Zeitlinger6, Wilhelm Huisinga4, Charlotte Kloft7. 1. Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universitaet Berlin, Berlin, Germany. 2. Graduate Research Training program PharMetrX, Berlin/Potsdam, Germany. 3. Havelland Kliniken GmbH, Hospital Pharmacy, Nauen, Germany. 4. Institute of Mathematics, University of Potsdam, Potsdam, Germany. 5. Clinical Pharmacometrics, Bayer AG, Berlin, Germany. 6. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. 7. Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universitaet Berlin, Berlin, Germany. charlotte.kloft@fu-berlin.de.
Abstract
PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches. RESULTS: Individual AUCISF estimates strongly varied for midpoint-NCA and midpoint-CA (≥52.3%CV) versus integral-CA (≤32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%-143%CVPK, integral-CA = 26.4%-72.6%CVPK) from recovery-related variability only in integral-CA (41.0%-50.3%CVrecovery). This also led to increased variability of AUCplasma for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (≤33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values. CONCLUSIONS: Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making.
PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches. RESULTS: Individual AUCISF estimates strongly varied for midpoint-NCA and midpoint-CA (≥52.3%CV) versus integral-CA (≤32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%-143%CVPK, integral-CA = 26.4%-72.6%CVPK) from recovery-related variability only in integral-CA (41.0%-50.3%CVrecovery). This also led to increased variability of AUCplasma for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (≤33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values. CONCLUSIONS: Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making.
Entities:
Keywords:
levofloxacin; microdialysis; noncompartmental analysis; nonlinear mixed-effects modelling; probability of target-attainment
Authors: Markus A Zeitlinger; Friederike Traunmüller; Aiman Abrahim; Michael R Müller; Zeynep Erdogan; Markus Müller; Christian Joukhadar Journal: Int J Antimicrob Agents Date: 2007-01 Impact factor: 5.283
Authors: P G Ambrose; D M Grasela; T H Grasela; J Passarell; H B Mayer; P F Pierce Journal: Antimicrob Agents Chemother Date: 2001-10 Impact factor: 5.191
Authors: Christoph Dorn; David Petroff; Nancy Neumann; Alexander Kratzer; Nahed El-Najjar; Arne Dietrich; Charlotte Kloft; Markus Zeitlinger; Martin G Kees; Frieder Kees; Hermann Wrigge; Philipp Simon Journal: J Antimicrob Chemother Date: 2019-08-01 Impact factor: 5.790
Authors: M A Zeitlinger; B M Erovic; R Sauermann; A Georgopoulos; M Müller; C Joukhadar Journal: J Antimicrob Chemother Date: 2005-08-24 Impact factor: 5.790
Authors: Margreke J E Brill; Aletta P I Houwink; Stephan Schmidt; Eric P A Van Dongen; Eric J Hazebroek; Bert van Ramshorst; Vera H Deneer; Johan W Mouton; Catherijne A J Knibbe Journal: J Antimicrob Chemother Date: 2013-11-08 Impact factor: 5.790
Authors: Romuald Bellmann; Gerald Kuchling; Pejman Dehghanyar; Markus Zeitlinger; Erich Minar; Bernhard X Mayer; Markus Müller; Christian Joukhadar Journal: Br J Clin Pharmacol Date: 2004-05 Impact factor: 4.335
Authors: D Busse; P Simon; D Petroff; N El-Najjar; L Schmitt; D Bindellini; A Dietrich; M Zeitlinger; W Huisinga; R Michelet; H Wrigge; C Kloft Journal: Antimicrob Agents Chemother Date: 2022-05-23 Impact factor: 5.938
Authors: David Busse; Philipp Simon; Lisa Schmitt; David Petroff; Christoph Dorn; Arne Dietrich; Markus Zeitlinger; Wilhelm Huisinga; Robin Michelet; Hermann Wrigge; Charlotte Kloft Journal: Clin Pharmacokinet Date: 2021-12-11 Impact factor: 5.577
Authors: Johanna Seeger; Sebastian Guenther; Katharina Schaufler; Stefan E Heiden; Robin Michelet; Charlotte Kloft Journal: Antibiotics (Basel) Date: 2021-05-21